Related Party Transactions - Textual (Details) (USD $)	0 Months Ended		1 Months Ended				1 Months Ended				0 Months Ended	1 Months Ended				1 Months Ended				0 Months Ended			1 Months Ended		0 Months Ended		1 Months Ended							1 Months Ended	9 Months Ended	12 Months Ended	1 Months Ended			1 Months Ended			1 Months Ended					1 Months Ended		0 Months Ended			1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 30, 2013 Notes Notes Due February 1, 2033	Jan. 31, 2013 Notes Notes Due February 1, 2033	Sep. 30, 2009 Convertible Preferred Stock [Member]	Jun. 30, 2014 Common stock investments, available for sale Notes Notes Due February 1, 2033	Oct. 31, 2013 Zebra	Oct. 31, 2013 Zebra Series A Preferred Stock	Oct. 31, 2013 Zebra Restricted Stock	Feb. 29, 2012 Chromadex Corporation	Feb. 29, 2012 Biozone Pharmaceuticals Inc	Nov. 30, 2010 Fabrus Inc	Sep. 21, 2009 Cocrystal	Sep. 30, 2009 Cocrystal	Aug. 31, 2011 Mr. Rubin	Aug. 29, 2013 Mr. Rubin OPKO Biologics	Sep. 21, 2011 Mr. Rubin Biozone Pharmaceuticals Inc	Oct. 31, 2013 Equity Method Investee	Oct. 31, 2013 Equity Method Investee ARNO	Oct. 31, 2013 Equity Method Investee ARNO One Year Warrants	Oct. 31, 2013 Equity Method Investee ARNO Five Year Warrants	Jan. 16, 2014 Equity Method Investee Biozone	Jan. 16, 2014 Equity Method Investee Biozone	Jan. 02, 2014 Equity Method Investee Biozone	Dec. 31, 2013 Equity Method Investee Biozone	Jul. 31, 2012 Equity Method Investee Biozone	Jan. 02, 2014 Equity Method Investee Biozone Series B Convertible Preferred Stock	Jan. 02, 2014 Equity Method Investee MusclePharm Corporation [Member] Common stock investments, available for sale	Dec. 31, 2013 Equity Method Investee Sorrento	Jun. 30, 2009 Equity Method Investee Sorrento	Aug. 31, 2011 Dr Frost	Aug. 31, 2013 Dr Frost OPKO Biologics	Oct. 31, 2013 Dr Frost Zebra Series A Preferred Stock	Aug. 31, 2011 Dr. Hsiao	Jan. 31, 2013 Frost Gamma Investments Trust and Hsu Gamma Investment, L.P. Notes Notes Due February 1, 2033	Dec. 31, 2012 Avi Properties LLC sqft	Sep. 30, 2014 Teva FineTech	Dec. 31, 2013 Teva FineTech	Feb. 29, 2012 Scripps Research Institute	Feb. 29, 2012 Gamma Trust Chromadex Corporation	Feb. 29, 2012 Hsu Gamma Chromadex Corporation	Nov. 30, 2010 Gamma Trust and Hsu Gamma Fabrus Inc	Jun. 30, 2010 Academia Sinica	Sep. 30, 2009 Frost Group, LLC Installment	Aug. 31, 2012 Real Estate Holdings LLC	Nov. 30, 2007 Real Estate Holdings LLC sqft	Jul. 28, 2014 Real Estate Holdings LLC sqft	Feb. 29, 2012 Director Chromadex Corporation	Jun. 30, 2009 Dr Lerner Sorrento	Feb. 28, 2014 FTC Filings Dr. Hsiao	Oct. 31, 2013 FTC Filings Dr. Hsiao	May 01, 2013 Lab Space Agreement Dr. Hsiao	May 01, 2013 Lab Space Agreement Dr. Hsiao sqft	May 01, 2013 Consulting Agreement Dr. Hsiao	Oct. 31, 2013 Loans Receivable Fabrus	Dec. 31, 2013 License Agreement Early Termination Fee Equity Method Investee Sorrento	Sep. 30, 2014 Reimbursement Of Travel Expense Dr Frost	Sep. 30, 2013 Reimbursement Of Travel Expense Dr Frost	Sep. 30, 2014 Reimbursement Of Travel Expense Dr Frost	Sep. 30, 2013 Reimbursement Of Travel Expense Dr Frost	Dec. 31, 2015 Scenario, Forecast [Member] Real Estate Holdings LLC	Dec. 31, 2014 Scenario, Forecast [Member] Real Estate Holdings LLC
Related Party Transaction [Line Items]
Payments for Filing Fees																																																$ 280,000	$ 170,000
Invested in common shares					2,000,000						2,500,000	2,500,000					2,000,000			500,000								2,300,000
Private Placement Financing																30,000,000				2,750,000
Investment Owned, Balance, Shares						840,000											833,333				1,000,000										900,000
Warrants expiration period																		1 year	5 years
Warrants to purchase common shares									8,500,000.0									833,333	833,333		1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																		2.40	4.00		0.50
Investment Agreement, Requirement to Hold Rights to Board, Minimum Stock Percentage																	3.00%
Equity Method Investment, Ownership Percentage						23.50%																						33.33%
Shares Received As Gift							900,000
Area of Real Estate Property																																													22,000						5,000
Lessor Leasing Arrangements, Operating Leases, Term of Contract																																																		5 years
Contractual Obligation, Due in Fifth Year																																																				60,000
Beneficially owned held by members										13.00%			1.00%	5.00%	1.00%														36.00%	5.00%		6.00%						16.00%	1.00%							1.00%	1.00%
Debt face amount		175,000,000.0																															175,000,000
Period of lease																																		5 years
Square feet of laboratory																																		44,000										8,300
Payments of lease per month																																		18,000										18,000
Exceeds consumer price index																																		5.00%
Sale of API to TEVA																																			300,000	300,000
Fund for research agreement																																					900,000
Research agreement maturity period																																					5 years
Approximate funding for development of technology																																					200,000
Period for development of technology																																					3 years
Invested in common shares								1,000,000	1,700,000
Beneficially owned held by owners								1.50%
Convertible senior notes interest rate									10.00%
Par value									$ 0.20
Warrants duration									10 years												10 years
Exercise price per share									$ 0.40
Convertible debt, stock issued from conversion	2,396,145			10,974,431																			10,000,000
Biozone Pharmaceuticals Warrants Exercised																								7,700,000
Noncash or Part Noncash Divestiture, Shares Received																										1,200,000.0
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued																									1,000,000
Stock Conversion, Common Shares Issued upon Conversion																						205.08
Investment was part of financing for Fabrus																																								2,100,000
Increase (Decrease) in Due from Related Parties																																																					100,000
Related Party Transaction, Rate																																																					7.00%
Research and development agreement amount																																									200,000
Equity method investment, number of shares purchased			1,701,723
Previous investment by a group of investor																																										5,000,000
Additional investment by a group of investor																																										5,000,000
Number of equal installments payable for additional investment																																										2
Equity Method Investment, Realized Gain (Loss) on Disposal																											17,200,000
Related Party Transaction, Other Revenues from Transactions with Related Party																																																						2,700,000
Lease rent per month for fifth year																																												24,000
Credit for tenant improvements																																												30,000															103,000	113,000
Period of lease agreement																																											6 months
Operating Leases, Monthly Payments, Year One																																													57,000
Operating Leases, Monthly Payments, Year Five																																													65,000
Tenant Improvements, Offset Against Operating Lease in Next Twelve Months																																													216,000
Reimbursement paid to related party for travel																																																							$ 110,000	$ 19,000	$ 118,000	$ 37,000